PT  - JOURNAL ARTICLE
AU  - Lawrence D. Lazar
AU  - A. Michael Lincoff
TI  - Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
AID  - 10.3949/ccjm.76a.09116
DP  - 2009 Dec 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 707--714
VI  - 76
IP  - 12
4099  - http://www.ccjm.org/content/76/12/707.short
4100  - http://www.ccjm.org/content/76/12/707.full
SO  - Cleve Clin J Med2009 Dec 01; 76
AB  - Prasugrel (Effient) has been approved for reducing the risk of thrombotic complications in patients with acute coronary syndromes who are to undergo percutaneous coronary intervention. In a large clinical trial (N Engl J Med 2007; 357:2001–2005), prasugrel was superior to clopidogrel (Plavix), another drug of its class, in this situation. However, bleeding complications were more frequent with prasugrel, and so this drug should be avoided in patients at higher risk of bleeding.